Journal Image
Recent Patents on Anti-Cancer Drug Discovery
ISSN (Print): 1574-8928
ISSN (Online): 2212-3970
DOI: 10.2174/157489209788452812      Price:  $100

Ras-MAPK Pathway as a Therapeutic Target in Cancer - Emphasis on Bladder Cancer

Author(s): Pankaj P. Dangle, Boriana Zaharieva, Hongtao Jia and Kamal S. Pohar
Pages 125-136 (12)
The Ras-MAPK pathway is important to orchestrating a cells response to external and internal stimuli. This pathway is commonly dysregulated in cancer, including bladder cancer. Multiple components of this complex pathway have been identified as potential targets for drug development. After initial preclinical studies many drugs targeting the Ras-MAPK pathway are being studied in phase II clinical trials for advanced bladder cancer either alone or in combination with other chemotherapeutic agents. Drugs presently in clinical trials inhibit the tyrosine kinases, including FGFR, EGFR, ERBB2, and PDGF, either through small molecule tyrosine kinase, dual kinase or farnesyltransferase inhibitors. Recent drug patents targeting the Ras-MAPK pathway in cancer are becoming more selective with the potential for improved therapeutic response and better toxicity as compared to the more universal MAPK pathway inhibitors. In the present review we summarize the importance of the Ras-MAPK pathway in cancer with a focus on bladder cancer and discuss current drugs and recent patents (2004-2008) that target this important pathway in bladder cancer.
Bladder cancer, Ras-MAPK pathway, new potential therapeutic targets
Department of Urology, The Ohio State University Comprehensive Cancer Center, 4980, 456 West 10th Avenue, Columbus, Ohio 43210, USA.